Company intelligence / Profile preview
IGC Pharma
Potomac, Maryland, United Statesigcpharma.com ↗
- Ownership
- Public · IGC
- Employees
- ~67
- Development stage
- Phase 2
01
Overview
IGC Pharma’s lead candidate, IGC-AD1, is in a Phase 2b clinical trial targeting agitation in dementia due to Alzheimer’s disease. Early results are promising for addressing neuroinflammation and behavioral symptoms. Other pipeline assets are at preclinical stages targeting amyloid plaques and tau pathology.
- Therapeutic areas
- Neurology
- Modalities
- Small moleculesPhytocannabinoid-based therapies
- Industry
- Biotech
02
Drug pipeline
17 assets16 more assets in the full pipeline.
Request access →03
Financials
- Market cap
- $29M
- Total revenue
- $265K
- Enterprise value
- $29.7M
Beyond the preview
Go deeper on IGC Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IGC Pharma.